Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes
- 30 June 2009
- journal article
- other
- Published by Elsevier BV in Atherosclerosis
- Vol. 204 (2), 342-344
- https://doi.org/10.1016/j.atherosclerosis.2008.09.026
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathwayCurrent Opinion in Cardiology, 2008
- Lipoprotein Management in Patients With Cardiometabolic RiskDiabetes Care, 2008
- The ‘Forgotten’ Bile Acid Sequestrants: Is Now a Good Time to Remember?Clinical Journal of Sport Medicine, 2007
- Results of the glucose-lowering effect of WelChol study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetesClinical Therapeutics, 2007
- Effects of Insulin Resistance and Type 2 Diabetes on Lipoprotein Subclass Particle Size and Concentration Determined by Nuclear Magnetic ResonanceDiabetes, 2003